Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial

2017 The lancet. Gastroenterology & hepatology 2;7 (494-500)

BACKGROUND: Clinical studies have shown high rates of sustained virological response (hepatitis C virus [HCV] RNA

Pubmed : 28416221